FDA updates mifepristone safety study status

Ella Jeffries / beckershospitalreview - The FDA updated its mifepristone guidance, detailing ongoing work on a safety study and the current status of the drug’s Risk Evaluation and Mitigation Strategy program. According to an April 8 news release, the agency said it is still collecting and eval…

AI Summary: The FDA updated the safety review status for mifepristone, yet the regulatory change hasn’t translated into widespread retail availability. Many community pharmacies are still hesitant to dispense the drug due to logistical, legal and reputational concerns, leaving access limited despite federal moves intended to broaden distribution — so yes, policy changed, but practice lagged.

'I'm not being listened to' - new health plan launched as women say they are still ignored

bbc - New plans to improve healthcare for women and girls have been set out, but will they change anything?

AI Summary: Health officials unveiled a new women's health plan, but many women say the rollout feels performative and that their concerns remain unheard. Patient advocates warn the initiative risks repeating past mistakes unless it embeds lived experience, transparent accountability and genuine co-design—otherwise it's policy theater with a glossy brochure.